Period:
Draw Mode:
| Volume | 84,426 |
|
|||||
| News | - | ||||||
| Day High | 1.85 | Low High |
|||||
| Day Low | 1.76 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Talaris Therapeutics Inc | TALS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.01 | -0.56% | 1.77 | 16:00:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.76 | 1.76 | 1.85 | 1.77 | 1.78 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 467 | 84,426 | $ 1.81 | $ 152,440 | - | 0.89 - 10.65 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:49:40 | 4 | $ 1.77 | USD |
Talaris Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 73.85M | 41.72M | 24.18M | $ - | $ - | -1.27 | -1.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.47M | 10.10% |
Talaris Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TALS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.90 | 1.92 | 1.65 | 1.76 | 326,966 | -0.13 | -6.84% |
| 1 Month | 1.93 | 2.15 | 1.65 | 1.86 | 206,595 | -0.16 | -8.29% |
| 3 Months | 1.08 | 2.15 | 1.04 | 1.72 | 408,851 | 0.69 | 63.89% |
| 6 Months | 2.44 | 2.86 | 0.89 | 1.60 | 315,447 | -0.67 | -27.46% |
| 1 Year | 9.00 | 10.65 | 0.89 | 2.40 | 223,009 | -7.23 | -80.33% |
| 3 Years | 17.25 | 19.82 | 0.89 | 5.56 | 164,023 | -15.48 | -89.74% |
| 5 Years | 17.25 | 19.82 | 0.89 | 5.56 | 164,023 | -15.48 | -89.74% |
Talaris Therapeutics Description
| Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. |